X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (36) 36
male (36) 36
index medicus (35) 35
abiraterone acetate (29) 29
aged (26) 26
middle aged (23) 23
prostate cancer (23) 23
metastasis (21) 21
oncology (21) 21
cancer (20) 20
chemotherapy (20) 20
urology (19) 19
prednisone (18) 18
aged, 80 and over (16) 16
antineoplastic combined chemotherapy protocols - therapeutic use (16) 16
docetaxel (16) 16
neoplasm metastasis (16) 16
prostatic neoplasms, castration-resistant - drug therapy (16) 16
survival (16) 16
prostatic neoplasms, castration-resistant - pathology (15) 15
double-blind method (14) 14
prednisone - administration & dosage (14) 14
prostatic neoplasms - drug therapy (14) 14
treatment outcome (14) 14
urology & nephrology (14) 14
disease-free survival (13) 13
article (12) 12
care and treatment (12) 12
men (12) 12
adult (11) 11
corticosteroids (11) 11
disease progression (11) 11
prostate-specific antigen - blood (11) 11
therapy (11) 11
analysis (10) 10
cyp17 (10) 10
acetates (9) 9
antineoplastic agents, hormonal - therapeutic use (9) 9
orchiectomy (9) 9
prostatic neoplasms - pathology (9) 9
antineoplastic combined chemotherapy protocols - adverse effects (8) 8
clinical-trials (8) 8
end-points (8) 8
kaplan-meier estimate (8) 8
metastatic castration-resistant prostate cancer (8) 8
original reports (8) 8
prednisone - therapeutic use (8) 8
research (8) 8
steroid 17-alpha-hydroxylase - antagonists & inhibitors (8) 8
taxoids - therapeutic use (8) 8
androgen antagonists - therapeutic use (7) 7
antineoplastic agents - therapeutic use (7) 7
antineoplastic agents, hormonal - adverse effects (7) 7
inhibitor (7) 7
patient outcomes (7) 7
prostatic neoplasms, castration-resistant - blood (7) 7
recommendations (7) 7
working group (7) 7
androstadienes - administration & dosage (6) 6
androstadienes - therapeutic use (6) 6
double-blind (6) 6
enzalutamide (6) 6
mitoxantrone plus prednisone (6) 6
oncology, experimental (6) 6
prostatic neoplasms - mortality (6) 6
prostatic neoplasms, castration-resistant - mortality (6) 6
risk factors (6) 6
survival analysis (6) 6
survival rate (6) 6
trial (6) 6
abiraterone acetate - administration & dosage (5) 5
abiraterone acetate - adverse effects (5) 5
androgens (5) 5
androstenes (5) 5
androstenes - administration & dosage (5) 5
androstenes - therapeutic use (5) 5
bone neoplasms - secondary (5) 5
clinical trials (5) 5
hematology, oncology and palliative medicine (5) 5
hormonal-therapy (5) 5
increased survival (5) 5
medical research (5) 5
metastases (5) 5
placebo (5) 5
placebo-controlled phase-3 (5) 5
prednisone - adverse effects (5) 5
prognosis (5) 5
proportional hazards models (5) 5
prostate-specific antigen (5) 5
prostatic neoplasms - blood (5) 5
testosterone (5) 5
time factors (5) 5
abiraterone (4) 4
abiraterone acetate - therapeutic use (4) 4
abridged index medicus (4) 4
androstadienes - adverse effects (4) 4
androstenols - therapeutic use (4) 4
antiandrogen withdrawal (4) 4
antineoplastic combined chemotherapy protocols (4) 4
circulating tumor-cells (4) 4
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 07/2017, Volume 377, Issue 4, pp. 352 - 360
The addition of abiraterone, a drug that blocks endogenous androgen synthesis, to standard androgen-deprivation therapy in patients with newly diagnosed,... 
Androgen Antagonists | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols | Male | Randomized Controlled Trial | Abiraterone Acetate | Journal Article | Prostatic Neoplasms | Clinical Trial, Phase III | Neoplasm Metastasis | Research Support, Non-U.S. Gov't | Survival Analysis | Aged, 80 and over | Adult | Multicenter Study | Aged | Prednisolone | Steroid 17-alpha-Hydroxylase | ANDROGEN-DEPRIVATION THERAPY | MEDICINE, GENERAL & INTERNAL | RECOMMENDATIONS | PLACEBO-CONTROLLED PHASE-3 | SURVIVAL ANALYSIS | CLINICAL-TRIALS | DOUBLE-BLIND | LEUPROLIDE ACETATE | DOCETAXEL | CHEMOTHERAPY | NEOADJUVANT | Prednisolone - adverse effects | Steroid 17-alpha-Hydroxylase - antagonists & inhibitors | Prostatic Neoplasms - radiotherapy | Prednisolone - administration & dosage | Prostatic Neoplasms - surgery | Abiraterone Acetate - adverse effects | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Prostatic Neoplasms - mortality | Abiraterone Acetate - administration & dosage | Neoplasm Metastasis - drug therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Androgen Antagonists - therapeutic use | Androgen Antagonists - administration & dosage | Androgen Antagonists - adverse effects | Prostatic Neoplasms - drug therapy | Androgen suppression therapy | Usage | Prednisone | Research | Prostate cancer | Medical research | Prostate-specific antigen | Clinical trials | Metastasis | Patients | Cancer therapies | Metastases | Androgens | Chemotherapy | Pain | Castration | Medical prognosis | Hypokalemia | Death | Prostate | Abiraterone Acetate/administration & dosage | Prednisolone/administration & dosage | Androgen Antagonists/administration & dosage | Medical and Health Sciences | Medicin och hälsovetenskap | Neoplasm Metastasis/drug therapy | Steroid 17-alpha-Hydroxylase/antagonists & inhibitors | Antineoplastic Combined Chemotherapy Protocols/adverse effects | Klinisk medicin | Clinical Medicine | Prostatic Neoplasms/drug therapy | Cancer and Oncology | Cancer och onkologi
Journal Article
Journal Article
Lancet Oncology, ISSN 1470-2045, 2015, Volume 16, Issue 2, pp. 152 - 160
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2012, Volume 13, Issue 12, pp. 1210 - 1217
Journal Article
Lancet Oncology, ISSN 1470-2045, 2013, Volume 14, Issue 12, pp. 1193 - 1199
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 01/2013, Volume 368, Issue 2, pp. 138 - 148
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 05/2011, Volume 364, Issue 21, pp. 1995 - 2005
Journal Article
Journal Article